

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

### SECTION 1. IDENTIFICATION

Product name : Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**


#### Hazards for the product as supplied

Reproductive toxicity : Category 1B  
Specific target organ toxicity : Category 1 (Immune system)  
- repeated exposure (Oral)

#### Other hazards

None known.

#### GHS label elements

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.  
H372 Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.  
P264 Wash skin thoroughly after handling.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

### Response:

P308 + P313 IF exposed or concerned: Get medical attention.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Pembrolizumab	1374853-91-4*	$\geq 10 - \leq 30$	TSC
Sucrose	57-50-1*	$\geq 5 - \leq 10$	TSC
Berahyaluronidase alfa	2636716-20-4*	$> 0 - \leq 0.1$	TSC

\* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

Most important symptoms : May damage the unborn child.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

and effects, both acute and delayed  
Protection of first-aiders : Causes damage to organs through prolonged or repeated exposure if swallowed.  
: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  
Notes to physician : Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g., by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

---

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapors.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Pembrolizumab	1374853-91-4	TWA	450 µg/m <sup>3</sup> (OEB 2)	Internal
Sucrose	57-50-1	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respirable fraction)	5 mg/m <sup>3</sup>	OSHA Z-1
Berahyaluronidase alfa	2636716-20-4	TLV-C	0.06 ug/m <sup>3</sup> (OEB 5)	Internal
Further information: RSEN				
		Wipe limit	0.07 ug/100 cm <sup>2</sup>	

**Engineering measures** : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable. Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**

**Material** : Chemical-resistant gloves

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
7.0	05/09/2026	7723969-00021	Date of first issue: 01/06/2021

---

Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	5.5 No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics  
Particle size : Not applicable

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact

---

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

Ingestion  
Eye contact

### Acute toxicity

Not classified based on available information.

### Components:

#### Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

#### Berahyaluronidase alfa:

Acute oral toxicity : Remarks: Not classified due to lack of data.

Acute inhalation toxicity : Remarks: Not classified due to lack of data.

Acute dermal toxicity : Remarks: Not classified due to lack of data.

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

### Components:

#### Berahyaluronidase alfa:

Result : Sensitizer

### Germ cell mutagenicity

Not classified based on available information.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

### Components:

#### **Sucrose:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

#### **Berahyaluronidase alfa:**

Genotoxicity in vitro : Remarks: Not classified due to lack of data.

Genotoxicity in vivo : Remarks: Not classified due to lack of data.

Germ cell mutagenicity - Assessment : May cause genetic defects.

#### **Carcinogenicity**

Not classified based on available information.

### Components:

#### **Berahyaluronidase alfa:**

Remarks : Not classified due to lack of data.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

#### **Reproductive toxicity**

May damage the unborn child.

### Components:

#### **Pembrolizumab:**

Reproductive toxicity - Assessment : May damage the unborn child., Based on data from similar materials

#### **Berahyaluronidase alfa:**

Effects on fertility : Remarks: Not classified due to lack of data.  
May cause adverse reproductive effects.

Effects on fetal development : Remarks: Not classified due to lack of data.  
May cause birth defects.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

### STOT-single exposure

Not classified based on available information.

#### Components:

##### **Berahyaluronidase alfa:**

Assessment : May cause damage to organs.  
Remarks : Not classified due to lack of data.

### STOT-repeated exposure

Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

#### Components:

##### **Pembrolizumab:**

Target Organs : Immune system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

##### **Berahyaluronidase alfa:**

Assessment : May cause damage to organs through prolonged or repeated exposure.  
Remarks : Not classified due to lack of data.

### Repeated dose toxicity

#### Components:

##### **Pembrolizumab:**

Species : Monkey  
NOAEL : 200 mg/kg  
Application Route : Intravenous  
Exposure time : 180 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 200 mg/kg  
Application Route : Intravenous  
Exposure time : 180 d  
Remarks : No significant adverse effects were reported

##### **Berahyaluronidase alfa:**

Remarks : Not classified due to lack of data.  
May cause damage to organs.

### Aspiration toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

### Components:

#### **Berahyaluronidase alfa:**

|| Not applicable

### **Experience with human exposure**

### Components:

#### **Pembrolizumab:**

|| Inhalation : Target Organs: Immune system  
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis  
Remarks: Damage to fetus possible

#### **Berahyaluronidase alfa:**

|| General Information : Avoid repeated exposure.  
May cause eye, skin, and respiratory tract irritation.  
May be harmful if swallowed.  
May be harmful if inhaled.  
May produce an allergic reaction.  
May cause heritable genetic damage.  
May cause adverse reproductive effects.  
May cause birth defects.  
May cause damage to organs.

### **Further information**

### Components:

#### **Berahyaluronidase alfa:**

|| Remarks : The toxicological properties of this material have not been fully investigated

---

## SECTION 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

### Components:

#### **Berahyaluronidase alfa:**

|| Toxicity to fish : Remarks: No data available  
|| Toxicity to daphnia and other aquatic invertebrates : Remarks: No data available  
|| Toxicity to algae/aquatic plants : Remarks: No data available  
|| Toxicity to daphnia and other : Remarks: No data available

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

|| aquatic invertebrates (Chronic toxicity)

### Ecotoxicology Assessment

|| Acute aquatic toxicity : No data available

|| Chronic aquatic toxicity : No data available

### Persistence and degradability

#### Components:

#### Berahyaluronidase alfa:

|| Biodegradability : Remarks: No data available

|| Stability in water : Remarks: No data available

### Bioaccumulative potential

#### Components:

#### Sucrose:

|| Partition coefficient: n-octanol/water : Pow: < 1

### Mobility in soil

No data available

### Other adverse effects

No data available

### Endocrine disrupting properties

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

---

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 7.0      Revision Date: 05/09/2026      SDS Number: 7723969-00021      Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

---

### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

Not regulated as a dangerous good

### Special precautions for user

Not applicable

---

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Reproductive toxicity  
Specific target organ toxicity (single or repeated exposure)

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

Water	7732-18-5
Pembrolizumab	1374853-91-4
Sucrose	57-50-1

#### California Permissible Exposure Limits for Chemical Contaminants

Sucrose	57-50-1
---------	---------

### The ingredients of this product are reported in the following inventories:

CA. DSL : not determined

AICS : not determined

CN IECSC : not determined

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version  
7.0

Revision Date:  
05/09/2026


SDS Number:  
7723969-00021

Date of last issue: 12/08/2025  
Date of first issue: 01/06/2021

### SECTION 16. OTHER INFORMATION

#### Further information

##### NFPA 704:



##### HMIS® IV / CED:

HEALTH	*	3
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Pre-

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/08/2025
7.0	05/09/2026	7723969-00021	Date of first issue: 01/06/2021

vention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/09/2026

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8